“膠原蛋白第一股”鉅子生物今日起招股 入場費約5596港元
格隆匯10月25日丨今日,鉅子生物(2367.HK)發佈全球發售公告,公司擬發行22,608,800股股份,其中香港公開發售2,261,200股,國際發售20,347,600股,另有15%超額配股權;招股時間爲2022年10月25日至10月28日,發售價爲24.30港元-27.70港元,每手買賣單位200股,入場費約5595.84港元;高盛、中金公司爲聯席保薦人;預期股份將於2022年11月4日於聯交所主板掛牌上市。根據弗若斯特沙利文的資料,鉅子生物是2021年中國第二大專業皮膚護理產品公司(零售額爲人民幣60億元),同時從2019年起連續三年一直是中國最大的膠原蛋白專業皮膚護理產品公司(按零售額計)。公司重組膠原蛋白產品的旗艦品牌可麗金和可復美分別是2021年中國專業皮膚護理產品行業第三和第四暢銷品牌(零售額分別爲人民幣29億元及人民幣27億元)。截至最後實際可行日期,公司產品組合中共有106項SKU,涵蓋功效性護膚品、醫用敷料和保健食品的八大主要品牌,即可復美、可麗金、可預、可痕、可復平、利妍、欣苷及參苷。鉅子生物的收入主要來自銷售產品,即專業皮膚護理產品、保健食品及其他。招股書顯示,2019-2021年及2020年前5個月,公司收入分別爲人民幣9.57億元、11.90億元、15.52億元、7.23億元,同期淨利潤分別爲人民幣5.75億元、8.26億元、8.28億元、3.14億元,均保持穩健增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.